Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Why would they, AVXL is a scam.
Dr. Missleading aka Dr. Liar aka Dr. caffeine aka Dr. Printing press aka Dr. Toxicity.
Down 7 out of 8 days. The one day it was up, it was up only a penny.
Volume drying up not a good sign.
Many more red days to follow I'm afraid giving 6 months minimum before any news which has a 99% chance of being a failure anyways.
One trick pony's operating in a 99% failure rate field like NTRP make good pump and dumps, not much else.
Golden Corral forming.
Hooooooold Looooooooooongs.
I think you're misunderstanding/mischaracterizing the goal of the Cortellis report. It's not reviewing "drugs to watch in 2019" as you state.
It's coverage is of drugs set to enter the market in 2019:
"Seven drugs are set to enter the market in 2019 and achieve blockbuster status by 2023. Immune-related and genetic disorder products dominate the list, with a strong showing by orphan drugs and breakthrough treatments"
I don't think any of the bulls here thinks A-273 will enter the market in 2019. Do you?
Oh man, how this report relates to A-273 and AVXL is beyond me. There's absolutely no chance we get to market this year.
I’m sure we can influence the price action and notch it on its way.
I see now that this pattern was indeed in my reading of yesterday’s chart.
Avxl plunged and skyrocketed between $3.03 and $2.90 today.
The skyrocket from $2.90 to $2.93 at close is very bullish.
Fortunately, it didn't pathetically rise from $2.90 to $2.92 at close because $1.25 would have been the next wave of support.
Cortellis’ report on drugs to watch in 2019 somehow missed Bryostatin:
https://clarivate.com/wp-content/uploads/dlm_uploads/2019/03/LS000819_DrugsToWatch_Report_A4_2019_FA10.pdf
If it's going to $200 as you claim, what difference does it make?
I didn't buy shares because of the science, I bought them because of the orchestrated pump currently happening.
Easy money!
thought you were on the sidelines with NTRP waiting for it to hit $3.70 a share???
I'm definitely riding the NTRP train.
Pump is being executed well but the dump is inevitable nonetheless.
The music will stop and most won't have a chair left to sit on.
Chooo Chooo!
We "plunged" from $3.01 to $2.93 then skyrocketed from $2.93 to close at $2.98.
Another very bullish close in the green today.
If $2.95 to $2.86 is a "plunge", l would say skyrocketing from $2.86 to close at $2.97 is very bullish.
Just like the mainstream media, motley fool has no new ideas on Alzheimer's disease treatment.
I'm sure you are, how else could you spin it.
Motley fool article on Alz.
https://finance.yahoo.com/news/3-leading-alzheimer-apos-disease-160000882.html
Where's NTRP?
Jean Founteau and the motley fool were labeled credible when they posted negative articles about AVXL.
Let me guess, that has now changed.
Anavex must be getting closer to the target now, as we seem to taking more flak from those attempting to shoot A2-73 down
"Patients dosed with 20 ug had a dropout rate similar to placebo".
Seems NTRP is as effective as placebo. I'm sure Dr. Alkon disagrees.
NTRP has very compelling trials/science in Alzheimer's, which has no drugs that can reverse the symptoms. NTRP has a good shot at changing that.
Right now nobody is missing anything. There is no news, no pump. Why rush in?
Thank goodness the price of stocks are inefficient; creates situations where owning once-in-a-lifetime stocks is possible. NTRP may be one of them.
Only on a message board would someone refer to buy low and sell high as "pump and dump"
And since the data was released the share price is up 2 bucks.
Once they had access to the full data set, the data does look phenomenal.
The reason that NTRP dropped was because their initial release of their data (that they and others saw as good) were viewed as disappointing to investors. Dr Alkon in his interview goes over that in detail saying it was a mistake because the results when fully analyzed were phemonenal.
Invest--" because further safety testing is needed for trials with "I'm questioning will it be difficult to find eligible patients because of the 18 yrs and older age restriction ????
https://www.rettsyndrome.org/about-rett-syndrome/faq#Life
What is life expectancy?
Due to the rarity of RTT, very little has been published about long term prognosis and life expectancy. The U.S. Natural History Study has now provided consistent information that provides some insights. Most of those who have been identified are under 25 years of age. It is often difficult to identify older individuals due to the frequent lack of complete infant and childhood developmental records. However, studies have determined that a girl with RTT has a 100% chance of reaching age 10, a 90% chance of reaching age 20, a greater than 75% chance of reaching age 30, a greater than 65% chance of reaching age 40, and a greater than 50% chance of reaching age 50. This compares to a 50% survival probability to age 80 for the general U.S. female population. As women in their 40's and 50's are increasingly known over the coming years, it will be possible to adjust these numbers. As improved nutrition and overall care are provided, these probabilities are expected to improve. While these statistics show that life expectancy is less in RTT than in the general female population, it is not nearly as low as previously thought or as other similar neurological disorders.
Claytrader signaling to all his short buddies. Bad sign for longterm investors.
Dilution to fund the "IF".
Thanks for proving my previous statement of all pre-revenue biotech companies are pump and dumps until proven otherwise.
If you are so sure of "IF", I'll sell you my shares of NTRP for $10 right now.
Because of the money raise perhaps
If NTRP has recently found the cure to ALZ, MS, fragile X etc. as you claim, why are they trading less today than a year ago?
Doesn't make a lot of sense to me.
As a NTRP investor, maybe you can explain the above to me?
What was NTRP trading for a year ago?
“Brain Swelling?” Get Real.
Every pre-revenue bio-tech company is a pump and dump.
There is a reason why NTRP and AVXL is currently worth millions and not the billions some claim.
Trial results forthcoming will determine value, not FUD on a MB.
Hope you make millions on NTRP.
For me, I'm gonna play this for what it currently is. Dump then Pump. Wash rinse and repeat.
but his reputation is on the line more than mine lol. He probably cares more about his ha ha.
Yes I realize that. 6 months minimum IS the realistic timeline. This is the all-in Texas hold-em game I'm playing.
I've decided to play the current pump instead of just waiting for it crash back down into the 3.80 range when "pumped" news doesn't come and investors realize 6 months minimum is the realistic timeline.
Buy early dump late. Been easy money!